IDT Corporation

Profit saw double-digit growth in the last quarter


Freedom Broker sees 65% upside in fintech small cap IDT


BofA strategist Jill Carey Hall is not particularly upbeat on the long-term outlook for small caps and believes that investing in them is risky at the moment, <a href="https://www.cnbc.com/2025/03/11/stock-market-today-live-updates.html#:~:text=Bank%20of%20America%20%D0%BF%D1%80%D0%B5%D0%B4%D0%BF%D0%BE%D1%87%D0%B8%D1%82%D0%B0%D0%B5%D1%82%20%D0%BA%D0%BE%D0%BC%D0%BF%D0%B0%D0%BD%D0%B8%D0%B8%20%D1%81%D1%80%D0%B5%D0%B4%D0%BD%D0%B5%D0%B9%20%D0%BA%D0%B0%D0%BF%D0%B8%D1%82%D0%B0%D0%BB%D0%B8%D0%B7%D0%B0%D1%86%D0%B8%D0%B8%20%D0%BA%D0%BE%D0%BC%D0%BF%D0%B0%D0%BD%D0%B8%D1%8F%D0%BC%20%D0%BC%D0%B0%D0%BB%D0%BE%D0%B9%20%D0%BA%D0%B0%D0%BF%D0%B8%D1%82%D0%B0%D0%BB%D0%B8%D0%B7%D0%B0%D1%86%D0%B8%D0%B8">reports</a> CNBC. In the current situation, she urges investors to focus on mid-cap stocks.

BofA cools on small-cap stocks, recommends mid caps


ProMIS Neurosciences, Inc.

ProMIS Neurosciences, with a market <a href="https://www.marketwatch.com/investing/stock/pmn?mod=mw_quote_tab">capitalization</a> of about $24 million on the Nasdaq, started out as a developer of mad cow disease tests but has since shifted focus to treating Alzheimer’s and other neurodegenerative diseases. Bloomberg has <a href="https://www.bloomberg.com/news/articles/2025-01-10/alzheimer-s-drugs-from-lilly-novo-and-roche-in-focus-for-investors?sref=Y0jVLcFo&amp;utm_source=in_materials#:~:text=Investors%20seeking%20the%20next%20obesity%2Dlike%20market%20opportunity%20will%20be%20closely%20watching%20developments%20related%20to%20treatments%20for%20Alzheimer%E2%80%99s%20disease%20in%202025.">said</a> this space offers some of the most promising investment opportunities.

ProMIS, taking aim at Alzheimer’s, could have 900% upside


ProPetro Holding Corp.

Applied Digital Corporation

Freedom Holdings Corp.

Freedom Finance Global has dug up the five small-cap stocks that were most popular among hedge funds at the end of 2024. Three of the companies operate in the IT sector, the most favored with portfolio managers, who allocated more than a quarter of their portfolios to IT names. Another top-five company specializes in fintech, while the last is an oil and gas services firm.

Freedom Holding Corp. analytics names five most popular small-cap holdings

Eledon Pharmaceuticals, Inc.

Noble Capital Markets has <a href="https://www.channelchek.com/company/eldn">put out</a> a target price for Eledon Pharmaceuticals, a micro-cap maker of a drug to prevent transplant rejection, of $10 per share, more than double the stock’s <a href="https://www.marketwatch.com/investing/stock/eldn?mod=mw_quote_tab">current market value</a>. The Noble report <a href="https://www.channelchek.com/news-channel/eledon-pharmaceuticals-eldn-tegoprubart-used-in-pig-kidney-transplant-patient#:~:text=%D0%9C%D1%8B%20%D1%80%D0%B0%D1%81%D1%81%D0%BC%D0%B0%D1%82%D1%80%D0%B8%D0%B2%D0%B0%D0%B5%D0%BC%20%D1%8D%D1%82%D0%BE%D1%82%20%D0%B2%D1%8B%D0%B1%D0%BE%D1%80%20%D0%BA%D0%B0%D0%BA%20%D0%BF%D1%80%D0%B8%D0%B7%D0%BD%D0%B0%D0%BA%20%D1%82%D0%BE%D0%B3%D0%BE%2C%20%D1%87%D1%82%D0%BE%20%D0%B2%D1%80%D0%B0%D1%87%D0%B8%20%D1%81%D1%87%D0%B8%D1%82%D0%B0%D1%8E%D1%82%20%D0%B5%D0%B3%D0%BE%20%D0%BA%D0%BB%D0%B8%D0%BD%D0%B8%D1%87%D0%B5%D1%81%D0%BA%D0%B8%D0%B5%20%D0%B4%D0%B0%D0%BD%D0%BD%D1%8B%D0%B5%20%D1%83%D0%BB%D1%83%D1%87%D1%88%D0%B5%D0%BD%D0%B8%D0%B5%D0%BC%20%D0%BF%D0%BE%20%D1%81%D1%80%D0%B0%D0%B2%D0%BD%D0%B5%D0%BD%D0%B8%D1%8E%20%D1%81%20%D1%82%D0%B0%D0%BA%D1%80%D0%BE%D0%BB%D0%B8%D0%BC%D1%83%D1%81%D0%BE%D0%BC.">points out</a> that doctors recently selected Eledon’s experimental drug for use in a pig kidney transplant. Overall, if rejection issues are overcome, genetically modified animal organs could help address the shortage of donor organs.

Noble Capital Markets says micro-cap transplant drugmaker Eledon set to double

Evaxion A/S

Its AI models can shorten drug development timelines and reduce the risk of failure. 

Zacks sees over 600% upside in AI-powered biotech micro cap Evaxion

Fox Corporation

Cal-Maine Foods, Inc.

Douglas Dynamics, Inc.

InvestorPlace has highlighted four stocks in its newsletter that are worth buying amid a news cycle turbocharged by U.S. President Donald Trump. The companies vary in size, but all could generate returns for investors as markets whipsaw with Trump policy pivots, the financial news and research firm argues.

InvestorPlace names four stocks to buy on ‘Trump’s turbocharged news cycle’

The world’s largest cities are overcrowded, and there is <a href="https://www.worldbank.org/en/topic/urbandevelopment/overview?utm_source=in_materials">no end</a> in sight to their growth. This makes alternatives to traditional ground transportation <a href="https://www.kingsresearch.com/ru/air-taxi-market-473?utm_source=in_materials">increasingly</a> necessary. One of them is air taxis. In fact, JPMorgan <a href="https://www.cnbc.com/2023/03/01/jpmorgan-has-a-new-favorite-way-to-play-the-evtol-market.html?utm_source=in_materials">sees</a> the air taxi market reaching $1.0 trillion by 2040, versus <a href="https://www.kingsresearch.com/ru/air-taxi-market-473?utm_source=in_materials">just over</a> $3.5 billion in 2023.

The air taxi market is projected to grow to $1 trillion. What smaller companies could take off?

Zacks Small-Cap Research (Zacks SCR) <a href="https://s27.q4cdn.com/906368049/files/News/2025/Zacks_SCR_Research_02032025_PLX_Vandermosten.pdf?utm_source=in_materials">values</a> Protalix Biotherapeutics, a small Israeli drugmaker listed in the U.S., at nearly 500% higher than its current market price. The company stands out from peers because it already generates revenue and has recently paid off its debt. This, Zacks SCR points out, takes one of the primary risks associated with small-cap stocks off the table: Smaller companies need to raise capital and dilute shareholders in the process.

Micro-cap Protalix Biotherapeutics, focused on rare diseases, has 500% upside — Zacks SCR

Shares of Puerto Rican consulting firm Pharma-Bio Serv have the potential to rise 150% from current levels, according to Zacks Small-Cap Research (Zacks SCR). While the company had a bumpy 2024, its management is confident negative trends will reverse in 2025.

Zacks SCR says micro-cap Pharma-Bio Serv has 150% upside

<strong>Chip Skinner</strong>, who manages the Royce Smaller-Companies Growth Fund, has spotlighted ACV Auctions and Cantaloupe as two "high-confidence" holdings. The fund is part of Royce Investment Partners, founded by <a href="https://kz.kursiv.media/2024-08-15/mrdr-royce/?utm_source=in_materials">Wall Street legend</a> <strong>Chuck Royce</strong>, and <a href="https://www.royceinvest.com/funds/royce-smaller-companies-growth-fund/rvphx?utm_source=in_materials">invests</a> in companies that, in the words of Skinner, "look poised for multi-year periods of robust growth driven by sustainable competitive advantages and/or that appear to be benefiting from secular growth themes that create favorable conditions for the business."

Royce Growth Fund manager names two 'high-confidence' small-cap holdings

Piper Sandler expects the small- and mid-cap Russell 2000 index to outgain the large-cap S&amp;P 500 in 2025. The investment bank <a href="https://www.cnbc.com/amp/2025/01/28/stock-market-today-live-updates.html?utm_source=in_materials#:~:text=Johnson%20also%20expects%20the%20Russell%202000%20to%20outperform%20the%20500%2Dstock%20S%26P%20this%20year.">believes</a> that stocks of smaller companies offer investors the "most compelling opportunities," as the underlying businesses are bolstered by a robust labor market, rising productivity, and an overall strong U.S. economy.

Investment ideas